title: CACNB2: An Emerging Pharmacological Target for Hypertension, Heart Failure, Arrhythmia and Mental Disorders.
abstract: The voltage-gated Cav1.2 calcium channels respond to membrane depolarization by increasing the membrane permeability to Ca(2+), a major signal for cardiac muscle contraction, regulation of vascular tone and CREB-dependent transcriptional activation. CACNB2 is one of the four homologous genes coding for the auxiliary Cavβ subunits, which are important modulators of the Ca(2+) channel activity. Five serious mental disorders - autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia, - and three major cardiovascular diseases - hypertension, heart failure and sudden cardiac death, - have recently been linked to the CACNB2 gene coding for the Cavβ2 subunits. Here I will focus on the Cavβ2-specific molecular determinant β2-CED as an emerging pharmacological target.
authors.affiliation: Humgenex, Inc., Kensington, MD 20895, USA. soldatovn.humgenex@verizon.net.
authors.forename: Nikolai M
authors.initials: NM
authors.lastname: Soldatov
mesh_terms: D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D020746:Calcium Channels, L-Type / Q000187:drug effects* / Q000235:genetics; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D001523:Mental Disorders / Q000188:drug therapy*
chemical_list: C107597:CACNB2 protein, human; D020746:Calcium Channels, L-Type